Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticlePROCEEDINGS OF THE 20th ANNUAL MEETING OF THE SOCIETY OF BIOTHERAPEUTIC APPROACHES, 10 December, 2016 (Fukuoka, Japan)

Design and Synthesis of Novel Anti-metastatic Hypoxic Cytotoxin TX-2137 Targeting AKT Kinase

IKKYU SHIBA, RISA KOUZAKI, HISATSUGU YAMADA, YOSHIO ENDO, TAKAHISA TAKINO, HIROSHI SATO, KEIKO KITAZATO, TERUYOSHI KAGEJI, SHINJI NAGAHIRO and YOSHIHIRO UTO
Anticancer Research July 2017, 37 (7) 3877-3883;
IKKYU SHIBA
1Graduate School of Advanced Technology and Science, Tokushima University, Tokushima, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
RISA KOUZAKI
1Graduate School of Advanced Technology and Science, Tokushima University, Tokushima, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HISATSUGU YAMADA
2Institute of Technology, Industrial and Social Sciences, Tokushima University Graduate School, Tokushima, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YOSHIO ENDO
3Central Research Resource Branch, Cancer Research Institute, Kanazawa University, Kanazawa, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TAKAHISA TAKINO
3Central Research Resource Branch, Cancer Research Institute, Kanazawa University, Kanazawa, Japan
4Institute of Liberal Arts and Science, Kanazawa University, Kanazawa, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HIROSHI SATO
3Central Research Resource Branch, Cancer Research Institute, Kanazawa University, Kanazawa, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KEIKO KITAZATO
5Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TERUYOSHI KAGEJI
5Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SHINJI NAGAHIRO
5Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YOSHIHIRO UTO
2Institute of Technology, Industrial and Social Sciences, Tokushima University Graduate School, Tokushima, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: uto.yoshihiro@tokushima-u.ac.jp
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Background: The hypoxic microenvironment plays a crucial role in the malignant progression of tumor cells. Moreover, AKT, a serine/threonine kinase, is activated by various extracellular growth factors and is important for cell growth, survival, and motility of leukocytes, fibroblasts, endothelial cells, and tumor cells. Therefore, we aimed to design an anti-metastatic hypoxic cytotoxin which has inhibitory effects on AKT. Results: TX-2137 was designed and synthesized based on the structural similarity of a preexisting AKT1/2 kinase inhibitor and a hypoxic cytotoxin tirapazamine. TX-2137 effectively reduced the expression of phosphorylated AKT and matrix metalloproteinase 9 (MMP9) and showed strong inhibition of the proliferation of B16-F10, HT-1080, and MKN-45 cells. In addition, TX-2137 exhibited hypoxia-selective cytotoxicity towards A549 cells and inhibited liver metastasis of B16-F10 cells in a xenograft chick embryo model in the same way as doxorubicin. Conclusion: TX-2137 may be a potent lead compound in the development of a novel anti-metastatic AKT kinase inhibitor.

  • AKT
  • hypoxic cytotoxin
  • anti-metastatic agent
  • TX-2137

Hypoxia, a characteristic feature of many solid tumors, leads to chemoresistance, radioresistance, increased angiogenesis, vasculogenesis, invasion, metastasis, resistance cell death, genomic instability, and changes in metabolism (1-5). Tirapazamine (SR 4233) is a well-known drug that specifically exerts toxicity under such hypoxic conditions through the release of free radicals (6, 7). These free radicals, formed by natural decay of oxidized hydroxyl radical (OH•) or benzotriazinyl radical (BTZ•) following one-electron reduction of tirapazamine by NADPH-cytochrome 450 reductase, induce cytotoxicity by causing double-strand breakage of DNA (8). Tirapazamine is a prodrug that has advanced to phase III clinical trials (9, 10). A phase III clinical trial was conducted in patients with head and neck cancer with tirapazamine in combination with radiation or chemoradiation with cisplatin, but no significant differences in the 2-year overall survival and failure-free survival were reported when compared to patients treated with radiation plus cisplatin (11). However, the tirapazamine combination treatment with radiation plus cisplatin was effective when compared to chemoradiation with cisplatin and fluorouracil (9). The tirapazamine combination treatment is still feasible and its clinical trials are ongoing in patients with locally advanced cervical cancer and oropharyngeal cancer (NCT00094081, NCT00262821).

The phosphoinositide 3-kinase (PI3K)/AKT signal pathway is the most frequently activated signal transduction pathway in human cancer (12) and plays an important role in cell-cycle regulation, survival, migration, invasion, and metastasis of cancer cells (13-15). In addition, Young et al. reported that activated AKT accumulates in mitochondria under hypoxic conditions; changes various cellular responses and biological processes such as tumor metabolism to glycolytic system, apoptosis, and resistance to autophagy; alleviates oxidative stress, and maintains the growth of tumor cells faced with severe hypoxia (16). In this study, we, therefore, designed and synthesized an anti-metastatic hypoxic cytotoxin with AKT-inhibitory activity.

Materials and Methods

Materials. Nuclear magnetic resonance (NMR) 1H spectra were obtained using a JNM-EX400 spectrometer (Jeol, Tokyo, Japan) at 400 MHz. Solvents were evaporated under reduced pressure on a rotary evaporator. Thin-layer chromatography was performed on glass-backed silica gels (Merck 60 F254; Merck Japan, Tokyo, Japan) and components were visualized using ultraviolet (UV) light. Column chromatography was performed using a silica gel (60 N, spherical neutral; 40-50 μm; KANTO Chemical, Tokyo Japan). The molecular orbital structure was calculated by WinMOPAC 3.0 (PM3, Fujitsu, Kawasaki, Japan).

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Design of TX-2137 based on tirapazamine and AKT1/2 inhibitor.

Cell culture. B16-F10 mouse melanoma cells (kindly provided by Dr. Tsuruo, Tokyo University, Tokyo, Japan) and A549 human lung carcinoma cells (supplied by Dr. Kondo, Kyoto University, Kyoto, Japan) were maintained in Dulbecco's modified Eagle's medium (DMEM) (Wako Pure Chemical, Osaka, Japan), while HT-1080 human sarcoma cells (purchased from American type culture collection, Manassas, VA, USA) were cultured in Eagle's minimum essential medium (EMEM) (Wako Pure Chemical). MKN-45 human adenocarcinoma cells (Dr. Suzuki, Fukushima Medical College, Fukushima, Japan) and U87MG human neuronal glioblastoma cells (American Type Culture Collection Manassas, VA, USA) were maintained in RPMI-1640 medium (Wako Pure Chemical). All media were supplemented with 10% fetal bovine serum and cells were cultured in a humidified atmosphere of 5% CO2 at 37°C. Hypoxic culture was performed in a humidified atmosphere of 0.1% O2 at 37°C using an AnaeroPack (Mitsubishi Gas Chemical, Tokyo, Japan).

Synthesis of 3-chloro-1,2,4-benzotriazine 1-oxide. 2-Nitroaniline (10 g, 72.4 mmol; Sigma-Aldrich Japan, Tokyo, Japan) and cyanamide (6.0 g, 144.8 mmol; Tokyo Chemical, Tokyo, Japan) were melted at 100°C. Thereafter, 36% HCl (40 ml; Wako Pure Chemical) was slowly added and the mixture was stirred at 100°C for 2 h then the solution was cooled to room temperature. To this mixture, 7.5 M NaOH (200 ml; Wako Pure Chemical) was slowly added and stirred at 100°C for 2.5 h. Finally, the solution was cooled to room temperature and water (200 ml) was added and a substance precipitated from the solution was filtered with filter paper to yield compound 1 (3-amino-1,2,4-benzotriazine 1-oxide) as a yellow solid (17). 3-Amino-1,2,4-benzotriazine 1-oxide was dissolved in trifluoroacetic acid (60 ml; Wako Pure Chemical) at 5°C and sodium nitrite (4.8 g, 71.4 mmol; Tokyo Chemical, Tokyo, Japan) was added. The solution was stirred at room temperature for 2 h and was added dropwise to ice/water. The precipitate was filtered, washed with water, and dried. The solid produced (compound 2; 3-hydroxy-1,2,4-benzotriazine 1-oxide) was suspended in phosphoryl chloride (27 ml; Wako Pure Chemical) and N,N-dimethylformamide (5 ml; Wako Pure Chemical) and stirred at 100°C for 1 h. Once cooled, the solution was added dropwise to ice/water, the precipitate was filtered, washed with water, and dried. The precipitates were purified by silica-gel column chromatography with dichloromethane (CH2Cl2) to give compound 3 (3-chloro-1,2,4-benzotriazine 1-oxide) (1.9 g, 14.8% yield) (18).

Synthesis of TX-2137. 4-Aminophenol (1.0 g, 9.2 mmol; Tokyo Chemical) and imidazole (1.2 g, 18.3 mmol; Tokyo Chemical) were suspended in CH2Cl2 under a nitrogen atmosphere. tert-Butylchlorodimethylsilane (2.1 g, 13.7 mmol; Tokyo Chemical) was added and the solution was stirred at room temperature for 1 h, poured into saturated NaCl solution and extracted with CH2Cl2. The organic layer was evaporated to give compound 4 (1.5 g, 73.1% yield). Next, compound 4 (0.25 g, 1.1 mmol) was dissolved in CH2Cl2. Triethylamine (156 μl, 1.1 mmol; Wako Pure Chemical) and 3-chloro-1,2,4-benzotriazine 1-oxide (0.1 g, 0.6 mmol) were added and the solution was stirred at room temperature for 2 h, poured into water and extracted with CH2Cl2. The organic layer was evaporated and purified by silica-gel column chromatography with CH2Cl2 to give compound 5 (0.17 g, 84.1% yield). Next, compound 5 (0.1 g, 0.27 mmol) and NaHCO3 (0.045 g, 0.54 mmol; Wako Pure Chemical) were dissolved in CH2Cl2. m-Chloroperoxybenzoic acid (m-CPBA) (0.093 g, 0.54 mmol; Tokyo Chemical) was added and the mixture stirred at room temperature for 24 h. The solution was collected using a filter paper, the filtrate was evaporated and the residue was purified by silica-gel column chromatography with ethyl acetate (EtOAc) and EtOAc/methanol (MeOH), forming compound 6 (0.062 g, 54.9% yield). Finally, compound 6 (0.61 g, 1.6 mmol) was dissolved in tetrahydrofuran at 5°C and 1.0 M of tetrabutylammonium fluoride solution (3.2 ml, 3.2 mmol; Sigma-Aldrich Japan) was added. The solution was stirred at room temperature for 5 min, solvents were evaporated and the residue was purified by silica-gel column chromatography with 10%-MeOH/EtOAc to obtain compound 7 (TX-2137) (0.37 g, 84.7% yield) in the form of a purple powder; 1H NMR [(CD3)2SO] δ 9.96 (s, 1H, PhOH), 9.41 (s, 1H, PhNH), 8.22 (t, J=8.5 Hz, 2H), 7.97 (td, J=7.8, 1.4 Hz, 1H), 7.61 (td, J=7.8, 1.4 Hz, 1H), 7.38 (d, J=8.7 Hz, 2H), 6.79 (d, J=8.7 Hz, 2H); MS (EI) m/z 270 (M+, 13), 254 (68), 238 (56), 210 (100); Anal. calcd for C13H10N4O3: C, 57.78; H, 3.73; N 20.73. Found C, 57.56; H, 3.76; N, 20.75.

Figure 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

Synthesis of the TX-2137. Reagents: a: Cyanamide, 36% HCl, 7.5 M NaOH; b: Trifluoroacetic acid, sodium nitrite; c: phosphoryl chloride, N,N-dimethylformamide; d: tert-butylchlorodimethylsilane, imidazole, CH2Cl2; e: triethylamine, CH2Cl2; f: m-chloroperoxybenzoic acid, NaHCO3, CH2Cl2; g: 1.0 M of tetrabutylammonium fluoride solution, tetrahydrofuran.

In vitro WST-8 assay to evaluate the effect of TX-2137 on cell proliferation. In vitro cell proliferation was examined using a colorimetric assay with Cell Counting Kit-8 (Dojindo Laboratories, Kumamoto, Japan) according to the manufacturer's instructions. Briefly, B16-F10, HT-1080 and MKN-45 cells were seeded at a density of 5×103 cells/well in a 96-well plate and TX-2137, dissolved in dimethyl sulfoxide, was added to the culture medium at concentrations between 0.1-100 μM. After 72 h incubation, the medium was replaced with fresh medium containing the WST-8 reagent. After 3 h, the absorbance in each well was determined at 450 nm (with a reference wavelength of 620 nm) using an ImmunoMini NJ-2300 microplate spectrophotometer (BioTec, Tokyo, Japan, Tokyo, Japan). The percentage of cell growth inhibition was calculated by applying the following formula: % of cell growth inhibition=(1-[T/C]) ×100, where C and T were the mean absorbances of the control group and treated group, respectively. The 50% inhibitory concentration (IC50) value was measured graphically from the dose–response curve with at least three drug concentration points.

In vitro hypoxia-selective cytotoxicity of TX-2137 using WST-1 assay. A549 cells were seeded in two 96-well plates at a density of 3×103 cells/well and incubation for 24 h. After 24 h, TX-2137 was added at the final concentrations of 0.1 to 30 μM and each plate was incubated either normoxic (21% O2) or hypoxic (0.1% O2) conditions for 24 h. After 24 h, each well was washed with 1×PBS and fresh medium containing the WST-1 reagent (Wako Pure Chemical) was added. The absorbance was measured at a wavelength of 450 nm using a Tecan Infinite M200 microplate reader (Tecan, Männedorf, Switzerland).

AKT inhibition by TX-2137 by western blot analysis on U87MG cells. The harvested cells were homogenized in RIPA buffer (Thermo Scientific, IL, USA) supplemented with protease inhibitors (cOmplete™, Mini, EDTA-free®, Roche Applied Science Tokyo, Japan). After 5 min of centrifugation at 13,000 × g, the protein concentration in the supernatant was assayed with BCA reagent (PIERCE, Tokyo, Japan). After reduction in 60 mM Tris-HCl buffer (pH 6.8) containing 10% glycerol, 2% sodium dodecyl sulfate (SDS), 100 mM dithiothreitol (DTT) and 0.002% bromophenol blue, 50 μg of protein were separated by SDS-polyacrylamide gel electrophoresis and transferred to polyvinylidene fluoride (BIO-RAD, Hercules, CA, USA) membranes. The membranes were immersed for 1 h in blocking buffer [5% non-fat dry milk or 5% bovine serum albumin (in tris-buffered saline and then incubated with primary antibodies to AKT1, AKT2, AKT3 (1:1,000; Cell Signaling, Danvers, MA, USA), or phospho-AKT (Ser473) (1:2,000; Cell Signaling in Can Get Signal Solution 1 (TOYOBO, Osaka, Japan). The membranes were subsequently incubated with horseradish peroxidase-conjugated secondary antibodies in Can Get Signal Solution 2 (dilution 1:3,000; TOYOBO). The protein–antibody complexes were detected with Amersham ECL® plus (GE Healthcare, Little Chalfont, Buckinghamshire, UK) using a Lumino image analyzer (Image Quant LAS4000 mini; GE Healthcare) and NIH ImageJ 1.46 software (http://rsb.info.nih.gov/ij/). Each experiment was repeated three times.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table I.

Cell proliferation inhibitory activity (A) and hypoxic cytotoxicity (B) of TX-2137.

Figure 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 3.

AKT inhibition assay of TX-2137 by western blot analysis and the cell viability in U87MG cells. Each experiment was performed four times, data are the mean±SD. A: Western blot analysis to detect AKT protein expression in U87MG cells. Quantitative analysis using Image J (B, C) and the effect of TX-2137 on the cell viability of U87MG (D). Significantly different from the control at *p<0.05.

Assay of MMP9 inhibition by TX-2137 by gelatin zymography. To analyze the effect of TX-2137 on the activation of pro-MMP2 into its activated form which is induced by MT1-MMP and on the expression and secretion of MMP2 and MMP9, HT1080 cells (5×104 cells/ml) were seeded into a 48-well culture plate and cultured in 100 μl of complete media for 24 h. After washing twice with serum-free DMEM, the cells were further cultured in OPTI-MEM (Invitrogen) with various concentrations of TX-2137 for 3 h. Then, an aliquot of conditioned medium was analyzed by gelatin zymography. Zymography was performed with an 10% SDS-polyacrylamide gel containing 0.1% gelatin as described previously (19). After electrophoresis, SDS was replaced by Triton X-100, followed by overnight incubation in Tris-based buffer. Gels were stained with Coomassie Brilliant Blue, and gelatinolytic activity of MMP2 and MMP9 was detected as clear bands in a background of uniform staining.

In vivo anti-metastatic activity of TX-2137 using chick embryo model. Fertilized chicken eggs (Plymouth Rock × White Leghorn) were obtained from the Goto Chicken Farm (Gifu, Japan). The assay was performed as originally described by Endo et al. (20). Briefly, 5×104 cells were injected into the chorioallantoic membrane (CAM) veins of the chicken egg with a 30G needle 11 days after fertilization and eggs were incubated for a further 3 days. TX-2137 (in 0.1 ml) or doxorubicin (Kyowa Hakko Kirin, Tokyo, Japan) was administered into the CAM vein. Doses were as follows: 40 μg/egg for doxorubicin, 62.5 μg/egg and 125 μg/egg for TX-2137. After drug administration, eggs were incubated for another 4 days. Embryo livers were then dissected 7 days after tumor cell injection, and the total DNA was extracted. A fragment of mouse β-globin gene in the oncogene-transformed cells that colonized liver tissue was amplified by 25 cycles of polymerase chain reaction (PCR) using species-specific primers. Each PCR cycle consisted of 1 min of denaturing at 94°C, 1 min of annealing at 50°C, and 1.5 min of extension at 72°C. The amplified fragment (633 base pairs) was separated by electrophoresis in a 1.2% agarose gel. The signal intensity of the band in agarose gel was measured using image processing program Image J. Oligonucleotide primers were as follows: sense primer Mgp1 (5’-GGA TCA GTT GCT CCT ACA TT-3’) and antisense primer Mgp5 (5’-TAT CCG AAC TCT TGT CAA CA-3’).

Statistical analysis. Data are expressed as the mean and standard deviations of at least three independent experiments. The statistical significance of the differences between the results was analyzed using Student's t-test. A p<0.05 was considered statistically significant.

Results

Design of TX-2137. We focused on the structural similarity of pre-existing AKT1/2 inhibitor and tirapazamine, found in the bicyclic on tirapazamine and tricyclic heteroaromatic ring of AKT1/2 inhibitor as shown by dot lines (Figure 1). We designed the simplified compound TX-2137 by removing the 1-(4-piperidyl)-2-benzimidazolinone moiety of the lead compound of the AKT1/2 inhibitor (21).

Synthesis of TX-2137. 3-Chloro-1,2,4-benzotriazine 1-oxide was synthesized using the method described by Pchalek et al. (18). Using 4-aminophenol as the starting material, the phenolic hydroxyl group was protected with tert-butylchlorodimethylsilane and coupled with 3-chloro-1,2,4-benzotriazine 1-oxide. Thereafter, the N-4 position was oxidized to dioxide and deprotected to obtain TX-2137 (Figure 2).

Cell proliferation-inhibitory activity and hypoxic cytotoxicity of TX-2137. We first evaluated anti-proliferative activity and hypoxia-selective cytotoxicity of TX-2137 in different tumor cells (Table I). Table IA shows the cell proliferation-inhibitory activity of TX-2137 that exhibited a strong anti-proliferative effect against all the tumor cell lines tested. Table IB shows the results of the cytotoxicity assay under normoxic and hypoxic conditions. TX-2137 showed hypoxia-preferential cytotoxicity against A549 cells but the hypoxia selectivity of TX-2137 (4.2-fold) was lower than that of tirapazamine (13.1-fold).

AKT-inhibitory activity of TX-2137 on U87MG cells. We evaluated the inhibitory activity of TX-2137 on AKT protein expression, its phosphorylation and cell viability (Figure 3). TX-2137 effectively down-regulated the expression of AKT2 and the phosphorylation of AKT (Figure 3A-C). TX-2137 reduced cell viability by about 50% at 10 μM after 24 and 72 h (Figure 3D). This result correlates with the inhibition of AKT2 expression and AKT phosphorylation by TX-2137.

Figure 4.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 4.

Effect of TX-2137 on matrix metalloproteinase 2 (MMP2) and MMP9. TX-2137 clearly inhibited expression of MMP9 in a concentration-dependent manner.

Inhibitory activity of TX-2137 on MMP9 production in HT-1080 cells. The inhibitory activity of TX-2137 on MMP9 production was evaluated by zymographic assay using HT-1080 cells. TX-2137 inhibited the production of MMP9, but did not alter MMP2 production and activation (Figure 4).

Anti-metastatic activity of TX-2137 using chick embryo model on B16-F10 cells. Anti-metastatic activity of TX-2137 was assayed using a xenograft model using chick embryo. TX-2137 effectively prevented liver metastasis of B16-F10 melanoma cells in the same way as doxorubicin (Figure 5).

Discussion

In this study, we designed and synthesized TX-2137, which is a novel anti-metastatic hypoxic cytotoxin with AKT inhibitory activity, and evaluated its antitumor and anti-metastatic activities using in vitro and in vivo assay systems. TX-2137 showed strong anti-proliferative activity against tumor cell lines, with IC50 values ranging from 1.8 to 3.7 μM. Hypoxia-selective activity of TX-2137, however, was lower than that of tirapazamine. TX-2137 showed potent cytotoxicity even under normoxic conditions and little difference was observed compared to hypoxic conditions owing to its higher electron affinity compared to tirapazamine as shown in Figure 1. However, TX-2137 is susceptible to reduction and its reduced form may be highly cytotoxic due to hydroxyl radical production even under normoxic conditions. TX-2137 selectively down-regulated the expression of AKT2 protein and phosphorylation of AKT; these findings indicate that the 1-(4-piperidyl)-2-benzimidazolinone moiety of AKT1/2 inhibitor is not essential for its activity.

Figure 5.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 5.

Evaluation of anti-metastatic activity of TX-2137 using the chick embryo model. Polymerase chain reaction analysis to detect liver metastases of B16-F10 melanoma (A) and quantitative analysis of the signal intensity shown in (A) using the Image J software (B). Treatment with TX-2137 and doxorubicin led to significantly lower signal intensities than that of the control (*p<0.05).

MMP9, which is a downstream target of the AKT signaling pathway, plays an important role in invasion and metastasis of various cancer types, and MMP9 has been shown to be an important molecular target for the suppression of cancer metastasis (22). HT-1080 human fibrosarcoma cells were derived from a highly metastatic tumor and produce various MMPs including MMP2, MMP3, MMP9, and MMP14/MT1-MMP (23, 24). HT-1080 cells were shown to metastasize in xenograft models using nude mouse (25) and chick embryo (26-28). In the MMP-inhibitory assay here, TX-2137 inhibited MMP9 production in HT-1080 cells. Next, we evaluated the anti-metastatic activity of TX-2137 by using the chick embryo model because the chick embryo model provides a cost-effective, easily-accessible and rapid approach (29, 30). In this xenograft model, TX-2137 showed strong anti-metastatic activity against liver metastasis of B16-F10 melanoma.

From this study, TX-2137 appears to exhibit strong anti-metastatic activity through inhibition of AKT expression and phosphorylation, and suppression of MMP9 production.

In conclusion, we succeeded in the development of the anti-metastatic hypoxic cytotoxin TX-2137 possessing the inhibitory activity of AKT expression and MMP9 production.

  • Received May 2, 2017.
  • Revision received May 24, 2017.
  • Accepted May 29, 2017.
  • Copyright© 2017, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved

References

  1. ↵
    1. Collet G,
    2. Szade K,
    3. Nowak W,
    4. Klimkiewicz K,
    5. El Hafny-Rahbi B,
    6. Szczepanek K,
    7. Sugiyama D,
    8. Weglarczyk K,
    9. Foucault-Collet A,
    10. Guichard A,
    11. Mazan A,
    12. Nadim M,
    13. Fasani F,
    14. Lamerant FN,
    15. Grillon C,
    16. Petoud S,
    17. Beloeil JC,
    18. Jozkowicz A,
    19. Dulak J,
    20. Kieda C
    : Endothelial precursor cell-based therapy to target the pathologic angiogenesis and compensate tumor hypoxia. Cancer Lett 370: 345-357, 2016.
    OpenUrl
    1. Gilkes DM,
    2. Semenza GL,
    3. Wirtz D
    : Hypoxia and the extracellular matrix: drivers of tumour metastasis. Nat Rev Cancer 14: 430-439, 2014.
    OpenUrlCrossRefPubMed
    1. Graeber TG,
    2. Osmanian C,
    3. Jacks T,
    4. Housman DE,
    5. Koch CJ,
    6. Lowe SW,
    7. Giaccia AJ
    : Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 379: 88-91, 1996.
    OpenUrlCrossRefPubMed
    1. Muz B,
    2. de la Puente P,
    3. Azab F,
    4. Azab AK
    : The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy. Hypoxia Auckl 3: 83-92, 2015.
    OpenUrl
  2. ↵
    1. Lee C,
    2. Siu A,
    3. Ramos DM
    : Multicellular spheroids as a model for hypoxia-induced EMT. Anticancer Res 36: 6259-6263, 2016.
    OpenUrlAbstract/FREE Full Text
  3. ↵
    1. Hwang JT,
    2. Greenberg MM,
    3. Fuchs T,
    4. Gates KS
    : Reaction of the hypoxia-selective antitumor agent tirapazamine with a C1'-radical in single-stranded and double-stranded DNA: The drug and its metabolites can serve as surrogates for molecular oxygen in radical-mediated DNA damage reactions. Biochemistry 38: 14248-14255, 1999.
    OpenUrl
  4. ↵
    1. Brown JM,
    2. Wilson WR
    : Exploiting tumor hypoxia in cancer treatment. Nat Rev Cancer 4: 437-447, 2004.
    OpenUrlCrossRefPubMed
  5. ↵
    1. Yin J,
    2. Glaser R,
    3. Gates KS
    : Electron and spin-density analysis of tirapazamine reduction chemistry. Chem Res Toxicol 25: 620-633, 2012.
    OpenUrlPubMed
  6. ↵
    1. Rischin D,
    2. Peters L,
    3. Fisher R,
    4. Macann A,
    5. Denham J,
    6. Poulsen M,
    7. Jackson M,
    8. Kenny L,
    9. Penniment M,
    10. Corry J,
    11. Lamb D,
    12. McClure B
    : Tirapazamine, cisplatin, and radiation versus fluorouracil, cisplatin, and radiation in patients with locally advanced head and neck cancer: A randomized phase II trial of the Trans-Tasman Radiation Oncology Group (TROG 98.02). J Clin Oncol 23: 79-87, 2005.
    OpenUrlAbstract/FREE Full Text
  7. ↵
    1. Williamson SK,
    2. Crowley JJ,
    3. Lara PN Jr.,
    4. McCoy J,
    5. Lau DH,
    6. Tucker RW,
    7. Mills GM,
    8. Gandara DR
    ; Phase III trial of paclitaxel plus carboplatin with or without tirapazamine in advanced non-small-cell lung cancer: Southwest Oncology Group Trial S0003. J Clin Oncol 23: 9097-9104, 2005.
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Rischin D,
    2. Peters LJ,
    3. O'Sullivan B,
    4. Giralt J,
    5. Fisher R,
    6. Yuen K,
    7. Trotti A,
    8. Bernier J,
    9. Bourhis J,
    10. Ringash J,
    11. Henke M,
    12. Kenny L
    : Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): A phase III trial of the Trans-Tasman Radiation Oncology Group. J Clin Oncol 28: 2989-2995, 2010.
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. Agarwal E,
    2. Brattain MG,
    3. Chowdhury S
    : Cell survival and metastasis regulation by AKT signaling in colorectal cancer. Cell Signal 25: 1711-1719, 2013.
    OpenUrlCrossRefPubMed
  10. ↵
    1. King D,
    2. Yeomanson D,
    3. Bryant HE
    : PI3King the Lock: targeting the PI3K/AKT/mTOR pathway as a novel therapeutic strategy in neuroblastoma. J Pediatr Hematol Oncol 37: 245-251, 2005.
    OpenUrl
    1. Almhanna K,
    2. Strosberg J,
    3. Malafa M
    : Targeting AKT protein kinase in gastric cancer. Anticancer Res 31: 4387-4392, 2011.
    OpenUrlAbstract/FREE Full Text
  11. ↵
    1. Mayer IA,
    2. Arteaga CL
    : The PI3K/AKT pathway as a target for cancer treatment. Annu Rev Med 67: 11-28, 2016.
    OpenUrlCrossRefPubMed
  12. ↵
    1. Chae YC,
    2. Vaira V,
    3. Caino MC,
    4. Tang HY,
    5. Seo JH,
    6. Kossenkov AV,
    7. Ottobrini L,
    8. Martelli C,
    9. Lucignani G,
    10. Bertolini I,
    11. Locatelli M,
    12. Bryant KG,
    13. Ghosh JC,
    14. Lisanti S,
    15. Ku B,
    16. Bosari S,
    17. Languino LR,
    18. Speicher DW,
    19. Altieri DC
    : Mitochondrial AKT regulation of hypoxic tumor reprogramming. Cancer Cell 30: 257-272, 2016.
    OpenUrl
  13. ↵
    1. Hay MP,
    2. Gamage SA,
    3. Kovacs MS,
    4. Pruijn FB,
    5. Anderson RF,
    6. Patterson AV,
    7. Wilson WR,
    8. Brown JM,
    9. Denny WA
    : Structure–activity relationships of 1,2,4-benzotriazine 1,4-dioxides as hypoxia-selective analogues of tirapazamine. J Med Chem 46: 169-182, 2003.
    OpenUrlCrossRefPubMed
  14. ↵
    1. Pchalek K,
    2. Hay MP
    : Stille coupling reactions in the synthesis of hypoxia-selective 3-alkyl-1,2,4-benzotriazine 1,4-dioxideanticancer agents. J Org Chem 71: 6530-6535, 2006.
    OpenUrlCrossRefPubMed
  15. ↵
    1. Sato H,
    2. Takino T,
    3. Okada Y,
    4. Cao J,
    5. Shinagawa A,
    6. Yamamoto E,
    7. Seiki M
    : A matrix metalloproteinase expressed on the surface of invasive tumor cells. Nature 370: 61-65, 1994.
    OpenUrlCrossRefPubMed
  16. ↵
    1. Endo Y,
    2. Seiki M,
    3. Uchida H,
    4. Noguchi M,
    5. Kida Y,
    6. Sato H,
    7. Mai M,
    8. Sasaki T
    : Experimental metastasis of oncogene-transformed NIH 3T3 cells in chick embryo. Jpn J Cancer Res 83: 274-280, 1992.
    OpenUrl
  17. ↵
    1. Lindsley CW,
    2. Zhao Z,
    3. Leister WH,
    4. Robinson RG,
    5. Barnett SF,
    6. Defeo JD,
    7. Jones RE,
    8. Hartman GD,
    9. Huff JR,
    10. Huber HE,
    11. Duggan ME
    : Allosteric AKT (PKB) inhibitors: discovery and SAR of isozyme selective inhibitors. Bioorg Med Chem Lett 15: 761-764, 2005.
    OpenUrlCrossRefPubMed
  18. ↵
    1. Itoh T,
    2. Tanioka M,
    3. Matsuda H,
    4. Nishimoto H,
    5. Yoshioka T,
    6. Suzuki R,
    7. Uehira M
    : Experimental metastasis is suppressed in MMP9-deficient mice. Clin Exp Metastasis 17: 177-181, 1999.
    OpenUrlCrossRefPubMed
  19. ↵
    1. Sato H,
    2. Kida Y,
    3. Mai M,
    4. Endo Y,
    5. Sasaki T,
    6. Tanaka J,
    7. Seiki M
    : Expression of genes encoding type IV collagen-degrading metalloproteinases and their inhibitor TIMPs in various human tumor cells. Oncogene 7: 77-83, 1992.
    OpenUrlPubMed
  20. ↵
    1. Abd El-Aziz SH,
    2. Endo Y,
    3. Miyamaori H,
    4. Takino T,
    5. Sato H
    : Cleavage of growth differentiation factor 15 (GDF15) by membrane type 1-matrix metalloproteinase abrogates GDF15-mediated suppression of tumor cell growth. Cancer Sci 98: 1330-1335, 2007.
    OpenUrlCrossRefPubMed
  21. ↵
    1. Ohta Y,
    2. Watanabe Y,
    3. Tabata T,
    4. Oda M,
    5. Hayashi Y,
    6. Endo Y,
    7. Tanaka M,
    8. Sasaki T
    : Inhibition of lymph node metastasis by an anti-angiogenic agent, TNP-470. Br J Cancer 75: 512-515, 1997.
    OpenUrlPubMed
  22. ↵
    1. Endo Y,
    2. Sasaki T,
    3. Harada F,
    4. Noguchi M
    : Specific detection of metastasized human tumor cells in embryonic chicks by the polymerase chain reaction. Jpn J Cancer Res 81: 723-726, 1990.
    OpenUrlCrossRef
    1. Tsuchiya Y,
    2. Endo Y,
    3. Sato H,
    4. Okada Y,
    5. Mai M,
    6. Sasaki T,
    7. Seiki M
    : Expression of type IV collagenases in human tumor cell lines that can form liver colonies in chick embryo. Int J Cancer 56: 46-51, 1994.
    OpenUrlPubMed
  23. ↵
    1. Li Z,
    2. Takino T,
    3. Endo Y,
    4. Sato H
    : Activation of matrix metalloproteinase (MMP)-9 by membrane-type-1 matrix metalloproteinase/MMP2 axis stimulates tumor metastasis. Cancer Sci 108: 347-357, 2017.
    OpenUrl
  24. ↵
    1. Wilson SM,
    2. Chambers AF
    : Experimental metastasis assays in the chick embryo. Curr Protoc Cell Biol 19: 19.6, 2004.
    OpenUrl
  25. ↵
    1. Uto Y,
    2. Tamatani D,
    3. Mizuki Y,
    4. Endo Y,
    5. Nakanishi I,
    6. Ohkubo K,
    7. Fukuzumi S,
    8. Ishizuka M,
    9. Tanaka T,
    10. Kuchiike D,
    11. Kubo K,
    12. Inui T,
    13. Hori H
    : Evaluation of the sonosensitizing activities of 5-aminolevulinic acid and Sn(IV) chlorine 6 in tumor-bearing chick embryos. Anticancer Res 34: 4583-4587, 2014.
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top

In this issue

Anticancer Research: 37 (7)
Anticancer Research
Vol. 37, Issue 7
July 2017
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Design and Synthesis of Novel Anti-metastatic Hypoxic Cytotoxin TX-2137 Targeting AKT Kinase
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
3 + 9 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Design and Synthesis of Novel Anti-metastatic Hypoxic Cytotoxin TX-2137 Targeting AKT Kinase
IKKYU SHIBA, RISA KOUZAKI, HISATSUGU YAMADA, YOSHIO ENDO, TAKAHISA TAKINO, HIROSHI SATO, KEIKO KITAZATO, TERUYOSHI KAGEJI, SHINJI NAGAHIRO, YOSHIHIRO UTO
Anticancer Research Jul 2017, 37 (7) 3877-3883;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Design and Synthesis of Novel Anti-metastatic Hypoxic Cytotoxin TX-2137 Targeting AKT Kinase
IKKYU SHIBA, RISA KOUZAKI, HISATSUGU YAMADA, YOSHIO ENDO, TAKAHISA TAKINO, HIROSHI SATO, KEIKO KITAZATO, TERUYOSHI KAGEJI, SHINJI NAGAHIRO, YOSHIHIRO UTO
Anticancer Research Jul 2017, 37 (7) 3877-3883;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Apremilast Induces Apoptosis of Human Colorectal Cancer Cells with Mutant KRAS
  • HB-EGF Is a Promising Therapeutic Target for Lung Cancer with Secondary Mutation of EGFRT790M
Show more PROCEEDINGS OF THE 20th ANNUAL MEETING OF THE SOCIETY OF BIOTHERAPEUTIC APPROACHES, 10 December, 2016 (Fukuoka, Japan)

Similar Articles

Keywords

  • Akt
  • hypoxic cytotoxin
  • anti-metastatic agent
  • TX-2137
Anticancer Research

© 2023 Anticancer Research

Powered by HighWire